Health Catalyst Capital Management

The firm targets companies operating at the intersection of healthcare delivery, data liquidity, and reimbursement. Its focus spans clinical workflow software, revenue-cycle management platforms, AI-powered diagnostic tools, provider enablement services, and tech-enabled care delivery models. The unifying characteristic across the portfolio is a business model anchored in regulatory tailwinds — such as value-based reimbursement mandates, interoperability rules, or decentralized trial frameworks — which generate contracted or annuity-like revenue streams with high retention rates.

The firm's mandate includes traditional control buyouts, growth-stage minority investments, complex carve-outs, and direct secondary transactions. This structure provides flexibility to engage founder-owned businesses that are not for sale in full, platform companies seeking growth capital ahead of a later exit, or syndicates where one existing investor wants partial liquidity. The direct secondaries capability, in particular, differentiates Health Catalyst Capital from many lower-mid-market peers that lack the mandate or LP consents to execute structured purchases of existing LP or shareholder interests.

Sourcing relies on the partners' domain networks built over two decades inside healthcare IT banking, operating, and investing circles. Kennedy's track record at Blue Ox and his earlier operating roles provide access to founder referrals and sell-side advisors running processes in digital health. Mian's investment banking tenure at Morgan Stanley gives the firm visibility into larger corporate carve-outs in healthcare technology. The firm's thesis depth — publishing views on reimbursement change and data regulation — also surfaces inbound deal flow from company founders who screen for specialist boards rather than generalist capital, according to industry sources.

The firm's mandate excludes earlier-stage venture investments with no commercial revenue, pure biopharma or drug-development assets, medical device hardware companies with heavy FDA PMA-route regulatory burdens, and brick-and-mortar healthcare services businesses that lack a material technology or data component. This discipline reflects the partners' view that reimbursable-code risk and FDA clinical-trial cycles introduce binary outcomes unsuitable for a private equity fund structure, while capital-light software and tech-enabled services produce the repeatable revenue profile the strategy requires.

The firm sources and underwrites investments primarily in North America, with disclosed portfolio activity concentrated in the United States. The strategy permits European healthcare IT investments where the regulatory frameworks — such as GDPR and the European Health Data Space — create analogous data- and reimbursement-driven business models to the US market. No publicly disclosed investments indicate active deployment in Asia-Pacific or Latin American healthcare markets.